For decades, omega-3 fatty acids were classified as passive anti-inflammatory nutrients—competing with arachidonic acid for the same enzymes and diluting pro-inflammatory eicosanoid production. That model was incomplete. In 2000, Charles Serhan’s laboratory at Harvard discovered that EPA and DHA serve as substrates for an entirely new class of lipid mediators that don’t suppress inflammation at all. They actively end it. These specialized pro-resolving mediators (SPMs)—resolvins, protectins, and maresins—revealed that inflammation resolution is not a passive decay but a tightly programmed biochemical process with its own dedicated signaling molecules.
What Are Specialized Pro-Resolving Mediators?
Specialized pro-resolving mediators are a family of endogenous lipid signaling molecules biosynthesized from the long-chain omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), as well as from docosapentaenoic acid (DPA) and arachidonic acid (which yields the lipoxins). The major SPM families derived from omega-3s include the E-series resolvins (RvE1, RvE2, RvE3) from EPA, the D-series resolvins (RvD1 through RvD6), protectins (PD1/NPD1), and maresins (MaR1, MaR2) from DHA.[1]
What distinguishes SPMs from classical anti-inflammatory drugs is their mechanism of action. NSAIDs and corticosteroids block the production of pro-inflammatory mediators. SPMs do something fundamentally different: they actively stimulate the cellular events required to terminate inflammation—macrophage clearance of apoptotic neutrophils, tissue repair, and return to homeostasis. Serhan termed this process “catabasis,” the active programmed return to health.[2]
How EPA and DHA Convert to SPMs
Transcellular Biosynthesis: SPM production typically requires cooperation between multiple cell types—often a neutrophil and a platelet, or a neutrophil and a macrophage—that share lipid intermediates across cell membranes. This transcellular biosynthesis explains why SPMs are produced specifically at sites of inflammation where these cells converge.[1]
Lipoxygenase Cascade: The enzymatic machinery driving SPM synthesis is built primarily from 5-lipoxygenase (5-LOX), 12-lipoxygenase (12-LOX), and 15-lipoxygenase (15-LOX), with aspirin-acetylated COX-2 providing an alternative entry point that generates the “aspirin-triggered” epimers (AT-RvD1, AT-LXA4). EPA is converted via 15-LOX and 5-LOX into E-series resolvins, while DHA undergoes 15-LOX-mediated conversion to a 17-hydroperoxy intermediate that is further processed into D-series resolvins and protectins, or via 12-LOX into maresins.[2]
Receptor-Mediated Signaling: Unlike classical eicosanoids that act broadly, SPMs bind to specific G-protein-coupled receptors at picomolar to nanomolar concentrations. RvE1 acts through ChemR23 (ERV1) and partially antagonizes BLT1. RvD1 signals through GPR32 (DRV1) and ALX/FPR2, the same receptor that binds lipoxin A4. These receptors are expressed on neutrophils, macrophages, and resolving tissue cells, providing cell-type-specific resolution signals.[3]
Class Switching of Lipid Mediators: During an acute inflammatory response, there is a temporal switch in lipid mediator production. Early-phase prostaglandins (particularly PGE2 and PGD2) paradoxically induce 15-LOX expression in neutrophils, programming the same cells that drove inflammation to subsequently produce SPMs. This built-in resolution switch is one of the most elegant features of the inflammatory program.[2]
Resolution Mechanisms
Neutrophil Trafficking: SPMs do not block neutrophil recruitment that has already occurred—rather, they prevent further neutrophil infiltration while accelerating clearance of those already at the site. RvE1 and RvD1 reduce neutrophil transendothelial migration at nanomolar concentrations and limit polymorphonuclear cell infiltration in murine models of peritonitis by 50% or more.[3]
Efferocytosis Enhancement: A central feature of inflammation resolution is the macrophage clearance of apoptotic neutrophils, a process called efferocytosis. Failure of efferocytosis underlies many chronic inflammatory diseases. Resolvins, protectins, and maresins all enhance macrophage efferocytosis and promote the polarization of macrophages from the pro-inflammatory M1 phenotype toward the pro-resolving M2 phenotype.[1]
Tissue Regeneration: Maresin-1, identified in 2009, was named for its role as a “macrophage mediator in resolving inflammation” but has subsequently been shown to actively promote tissue regeneration. In planaria, MaR1 accelerates head regeneration; in mammalian models, it promotes wound healing and reduces tissue fibrosis.[4]
Clinical Evidence
Cardiovascular Disease: Defective resolution is increasingly recognized as a driver of atherosclerosis. The REDUCE-IT trial demonstrated that high-dose icosapent ethyl (purified EPA, 4 g/day) reduced major adverse cardiovascular events by 25% in statin-treated patients with elevated triglycerides—a benefit that has been mechanistically linked, at least in part, to enhanced SPM production rather than triglyceride lowering alone.[5]
SPM Profiles in Human Disease: Lipidomic profiling of patients with cardiovascular disease, chronic pain, and rheumatoid arthritis has consistently shown reduced circulating SPMs and elevated SPM-to-leukotriene ratios that correlate with disease severity. Plasma RvD1 and lipoxin A4 concentrations are diminished in patients with vulnerable atherosclerotic plaques, while supplementation with EPA and DHA elevates measurable SPM intermediates including 18-HEPE and 17-HDHA in human serum.[3]
Pain and Neuroinflammation: SPMs have potent analgesic properties in animal models that are mechanistically distinct from opioid or NSAID pathways. RvE1, RvD1, RvD2, and neuroprotectin D1 (NPD1/PD1) reduce inflammatory and neuropathic pain at doses orders of magnitude lower than morphine, acting through ChemR23, GPR32, and TRPV1 modulation.[3]
Safety Profile
Because SPMs are endogenous metabolites produced from dietary omega-3 fatty acids, the safety considerations are primarily those of EPA and DHA supplementation itself. At standard doses of 1-4 g/day combined EPA + DHA, adverse effects are limited to mild gastrointestinal discomfort, fishy aftertaste, and a theoretical concern about bleeding risk that has not been borne out in large clinical trials including REDUCE-IT.[5]
An important nuance is that not all omega-3 preparations equally support SPM biosynthesis. The conversion to SPMs requires intact substrate delivery to the cells expressing the relevant lipoxygenases, and there is interindividual variability in lipoxygenase activity, polymorphisms in ALOX5 and ALOX15, and competition with the omega-6-derived arachidonic acid pool. Aspirin at low doses uniquely triggers production of epimeric “aspirin-triggered” SPMs by acetylating COX-2, which may explain part of aspirin’s resolution-promoting actions beyond platelet inhibition.[2]
SPMs vs Classical Anti-Inflammatory Approaches
NSAIDs: Non-steroidal anti-inflammatory drugs inhibit COX-1 and COX-2, blocking the production of pro-inflammatory prostaglandins. However, by inhibiting COX-2, they also prevent the class-switching event that initiates lipoxygenase-mediated SPM biosynthesis. This may explain the paradoxical observation that chronic NSAID use can delay resolution of certain inflammatory conditions, even while providing symptomatic relief.[2]
Corticosteroids: Glucocorticoids broadly suppress inflammatory gene expression but also impair efferocytosis and macrophage polarization required for resolution. SPMs, in contrast, specifically promote these resolution programs without immunosuppression—they do not interfere with host defense against pathogens.[1]
Fish Oil Supplementation: Standard fish oil supplementation provides EPA and DHA as substrates for endogenous SPM production but does not guarantee robust SPM biosynthesis in individuals with impaired lipoxygenase activity or chronic resolution failure. Direct administration of synthetic SPM analogs—several of which are in clinical development—bypasses these biosynthetic bottlenecks and may represent the next generation of resolution-targeted therapy.[4]
The reframing is significant: omega-3 fatty acids are not merely “anti-inflammatory” in the way NSAIDs are anti-inflammatory. They are biosynthetic precursors to an entire signaling system designed to actively terminate inflammation and restore tissue homeostasis. Understanding this distinction has clinical implications for how we dose omega-3s, how we combine them with other agents, and how we evaluate their therapeutic potential in chronic inflammatory disease.
References
- Serhan CN. “Pro-resolving lipid mediators are leads for resolution physiology.” Nature. 2014;510(7503):92-101.
- Serhan CN, Chiang N, Van Dyke TE. “Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators.” Nature Reviews Immunology. 2008;8(5):349-361.
- Serhan CN, Levy BD. “Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators.” Journal of Clinical Investigation. 2018;128(7):2657-2669.
- Serhan CN, Yang R, Martinod K, et al. “Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions.” Journal of Experimental Medicine. 2009;206(1):15-23.
- Bhatt DL, Steg PG, Miller M, et al. “Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.” New England Journal of Medicine. 2019;380(1):11-22.
